The opioid use disorder market includes pharmaceutical therapies as well as behavioral therapies that are employed for treating opioid use disorder. Opioid use disorder refers to problematic patterns of opioid use that lead to clinically significant impairment or distress. Some common symptoms include strong cravings for opioids, withdrawal symptoms when not taking opioids, and tolerance requiring higher doses for desired effects. Traditional pharmaceutical options for opioid use disorder treatment include buprenorphine and methadone maintenance therapies. Buprenorphine is a partial opioid agonist used for detoxification and maintenance treatment of opioid dependence. Methadone, a full opioid agonist, is primarily used for maintenance treatment of opioid use dependence. Newer non-opioid treatment options are also emerging in the market.
The global opioid use disorder market is estimated to be valued at US$ 3,236.55 Mn in 2023 and is expected to exhibit a CAGR of 8.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The opioid use disorder market is expected to experience significant growth driven by increasing awareness about various treatment options for opioid use disorder. According to the National Institute on Drug Abuse, over 2 million people in the United States suffered from substance use disorders related to prescription opioid pain relievers in 2018. As per statistics, almost 21 to 29% of patients prescribed opioids for chronic pain misuse them. The enhanced diagnosis of opioid use disorders accompanied with appropriate treatment options is expected to propel the market growth over the forecast period. Additionally, approval and launch of novel treatment therapies is also fueling the market growth. For instance, in 2020, USFDA approved Lucemyra (lofexidine), a non-opioid treatment for reducing withdrawal symptoms in adults with opioid use disorder. However, the high costs associated with opioid dependence treatments as well as social stigma regarding substance abuse might hamper the market growth.
Segment Analysis
There are three key segments in the opioid use disorder market – medication-assisted treatment (MAT), behavioral therapy, and recovery support services. The MAT segment currently dominates the market due to increasing adoption of medication therapies such as buprenorphine and methadone for long-term opioid use disorder treatment. These medications help reduce opioid misuse and promote recovery when combined with behavioral therapies and social support.
PEST Analysis
Political: Government reforms to expand insurance coverage for opioid addiction treatment and rise in awareness programs about opioid misuse are driving market growth. However, regulatory hurdles for new drug approvals hinder the market.
Economic: High economic burden of opioid misuse on healthcare systems and loss of productivity pushes governments to increase funding for addiction treatment and prevention. Rising disposable incomes also increase affordability for treatment.
Social: Social stigma associated with opioid addiction is declining with better understanding of it as a chronic disease rather than a moral failing. Support groups play a role in long-term recovery.
Technological: Digital therapeutic tools for opioid withdrawal symptoms monitoring and remote counseling/therapy sessions are being increasingly adopted. Wearables and sensors also help doctors optimize medication-assisted treatment programs.
Key Takeaways
Global Opioid Use Disorder Market Demand is expected to witness high growth driven by the rising prevalence of opioid addiction disorders due to surging opioid prescriptions.
North America currently dominates the market owing to the evolving regulatory scenario and availability of multi-modal treatment options in the region.
Key players operating in the opioid use disorder market are Moog Inc., Honeywell International Inc., AMETEK Inc. These key players are focusing on developing innovative digital therapies and drugs to expand treatment access and improve recovery outcomes.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
